Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)

Civelek, Erdinç; boyali, osman; Kabatas, Serdar

Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)

Osman BOYALI, (Sağlık Bilimleri Üniversitesi, Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye)

Erdinç CİVELEK, (Sağlık Bilimleri Üniversitesi, Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye)

Serdar KABATAŞ (Sağlık Bilimleri Üniversitesi, Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye)

Türk Nöroşirürji Dergsi

6 1

Yıl: 2020 Cilt: 30 Sayı: 3 Sayfa Aralığı: 466 - 474 Metin Dili: Türkçe İndeks Tarihi: 10-11-2021

Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)

Öz:

Travmatik Omurilik yaralanması dünya üzerinde 10.4-83 olgu / milyon / yıl insidansına sahiptir ve toplumda maddi ve manevikülfeti yüksek önemli bir morbidite nedenidir. Günümüzde patofizyolojisinin daha iyi anlaşılmasına rağmen, tedavide kord hasarınıönlemeyi amaçlayan nöroprotektif ve nöronal yeniden büyümeyi veya miyelinizasyonun iyileştirilmesini amaçlayan nörorejeneratifyaklaşımların klinik kullanımı maalesef bugüne kadar sınırlı kalmıştır. Yapılan son çalışmalarda mevcut yönetim stratejileri erkencerrahi dekompresyon ve fiksasyon, omurilik perfüzyonunu iyileştirmek için ortalama arter basıncının artırılması için vazopresörilaçların kullanımı, metilprednizolon, amantadin, tirilazad mesilat, nalokson, tirotropin releasing hormon, minosiklin, gliburit,magnezyum, granülosit koloni uyarıcı faktör, riluzol ve glisikidin gibi nöroprotektif ajanları, ayrıca miyelinle ilişkili inhibitörler (örn.Anti-Nogo antikorları [ATI-355]), Rho inhibitörü VX-210 / Cethrin, gangliosidler, fibroblast büyüme faktörü gibi nöral rejenerasyonuartırmayı amaçlayan tedavileri ve güncel yaklaşım olan kök hücre naklini içeren farmakolojik tedavinin güncel yöntemleri literatüreşliğinde gözden geçirildi.

Anahtar Kelime:

Conservative Treatment in Traumatic Spinal Cord Injury (Current Pharmacological Treatment Methods)

Öz:

Traumatic spinal cord injury has an incidence of 10.4-83 cases/million/year worldwide and is an important cause of morbidity with a high material and moral burden in the society. Despite the better understanding of the pathophysiology today, the clinical use of neuroprotective and neuronal regrowth or neuroregenerative approaches aimed at preventing cord injury in the treatment has been limited to date. Current management strategies in recent studies include early surgical decompression and fixation, the use of vasopressor drugs to increase the mean arterial pressure and improve spinal perfusion, and treatment with methylprednisolone, amantadine, thyylazad mesylate, naloxone, thyrotropin releasing hormone, minocycline, glyburide, magnesium, granulocyte factor and neuroprotective agents such as glycicidine, as well as myelin-related inhibitors (eg Anti-Nogo antibodies [ATI-355]) aimed at increasing neural regeneration, such as the Rho inhibitor VX-210/ Cethrin, gangliosides, fibroblast growth factor, and stem cell transplantation. Current methods of pharmacological treatment have been reviewed with the literature.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Ahmad FU, Wang MY, Levi AD: Hypothermia for acute spinal cord injury–a review. World Neurosurgery 82(1–2):207-214, 2014
2. Ahuja CS, Martin AR, Fehlings MG: Recent advances in managing spinal cord injury secondary to trauma. F1000 Research 5(F1000 Faculty Rev):1017, 2016
3. Akyuva Y, Diren F, Bulduk EB, Saraç ME, Kabataş S: Nöroşirürji’de kök hücre uygulamaları ve kök hücre tedavisindeki yenilikler. Türk Nöroşir Derg 28(3):366-371, 2018
4. Alibai EA, Baghban F, Farrokhi MR, Mohebali N, Ashraf MH: Effects of human erythropoietin on functional outcome of patients with traumatic cervical cord injury; a pilot randomised clinical trial. Bull Emerg Trauma 3(3):79-85, 2015
5. Allan RM, Aleksanderek I, Fehlings GM: Diagnosis and acute management of spinal cord injury: Current best practices and emerging therapies. Curr Trauma Rep 1:169-181, 2015
6. Badhiwala JH, Ahuja CS, Fehlings MG: Time is spine: A review of translational advances in spinal cord injury. J Neurosurg Spine 30(1):1-18, 2018
7. Berger R, Soder S: Neuroprotection in preterm infants. Biomed Res Int 2015:257139, 2015
8. Bracken MB, Shepard MJ, Hellenbrand KG: Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg 63(5):704-713, 1985
9. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinalcord injury: Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322(20):1405-1411, 1990
10. Bracken MB, Shepard MJ, Holford TR: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277(20):1597–1604, 1997
11. Bracken MB, Shepard MJ, Holford TR: Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1- year follow up. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. J Neurosurg 89:699– 706, 1998
12. Bradbury EJ, Moon LD, Popat RJ: Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416:636-640, 2002
13. Cappuccino A, Bisson LJ, Carpenter B, Snyder K, Cappuccino H: Systemic hypothermia as treatment for an acute cervical spinal cord injury in a Professional football player: 9-year follow-up. Am J Orthop Belle Mead NJ 46(2):79-82, 2017
14. Castro MM, Daltro C: Sleep patterns and symptoms of anxiety and depression in patients with chronic pain. Arq Neuropsiquiatr 67:25-28, 2009
15. Chen MS, Huber AB, van der Haar ME: Nogo- A is a myelinassociated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403(6768):434-439, 2000
16. ClinicalTrials.gov website. A phase I/II study to evaluate the safety and efficacy of intrathecal injection of KP-100IT in subjects with acute spinal cord injury. http://www.clinicaltrial. gov/ct2/show/ NCT02193334. Accessed November 20, 2014
17. ClinicalTrials.gov website. Acute safety, tolerability, feasibility and pharmacokinetics of intrath. administered ATI355 in patients with acute SCI. http://clinicaltrials.gov/show/ NCT00406016. Accessed November 21, 2014
18. Coutinho AE, Chapman KE: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335(1):2– 13, 2011
19. David S, Aguayo AJ: Axonal elongation into peripheral nervous system “bridges” after central nervous system injury in adult rats. Science 214(4523):931-933, 1981
20. De Laporte L, des Rieux A, Tuinstra HM: Vascular endothelial growth factor and fibroblast growth factor 2 delivery from spinal cord bridges to enhance angiogenesis following injury. J Biomed Mater Res A 98(3):372-382, 2011
21. DeFrates S, Cook AM: Pharmacologic treatment of neuropathic pain following spinal cord injury. Orthopedics 34: 203, 2011
22. Dergham P, Ellezam B, Essagian C: Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 22(15):6570– 6577, 2002
23. Dididze M, Green BA, Dietrich WD, Vanni S, Wang MY, Levi AD: Systemic hypothermia in acute cervical spinal cord injury: A case-controlled study. Spinal Cord 51(5):395-400, 2013
24. Dietrich WD, Levi AD, Wang M, Green BA: Hypothermic treatment for acute spinal cord injury. Neurotherapeutics 8:229-239, 2011
25. Donnelly EM, Lamanna J, Boulis NM: Stem cell therapy for the spinal cord. Stem Cell Res Ther 3(4):24, 2012
26. Fehlings MG, Theodore N, Harrop J: A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 28(5):787–796, 2011
27. Fehlings MG, Tetreault LA, Wilson JR, Kwon BK, Burns AS, Martin AR: A clinical practice guideline for the management of acute spinal cord injury: Introduction, rationale, and scope. Global Spine J 7 Suppl 3:84-94, 2017
28. Festoff BW, Ameenuddin S, Arnold PM: Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97:1314-1326, 2006
29. Flamm ES, Young W, Collins WF: A phase I trial of naloxone treatment in acute spinal cord injury. J Neurosurg 63(3):390- 397, 1985
30. Frantseva M, Perez Velazquez JL, Tonkikh A: Neurotrauma/ neurodegeneration and mitochondrial dysfunction. Prog Brain Res 137:171-176, 2002
31. Freund P, Schmidlin E,Wannier T: Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 12:790-792, 2006
32. Geisler FH, Coleman WP, Grieco G, Poonian D: The Sygen multicenter acute spinal cord injury study. Spine 26 Suppl 24:87-98, 2001
33. Goldschmidt Y, Sztal TE, Jusuf PR, Hall TE, Nguyen-Chi M, Currie PD: Fgf-dependent glial cell bridges facilitate spinal cord regeneration in zebrafish. J Neurosci 32(22):7477–7492, 2012
34. Grossman RG, Fehlings MG, Frankowski RF: A prospective, multicenter, phase I matchedcomparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma 31(3):239-255, 2014
35. Guan Y, Ding X, Cheng Y, Fan D, Tan L, Wang Y: Efficacy of pregabalin for peripheral neuropathic pain: Results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clin Ther 33:159-166, 2011
36. Guay DR: Pregabalin in neuropathic pain: A more “pharmaceutically elegant” gabapentin? Am J Geriatr Pharmacother 3:274-287, 2005
37. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F: Prevalence of self-reported neuropathic pain and impact on quality of life: A prospective representative survey. Acta Anaesthesiol Scand 2:132-136, 2008
38. Hadley MN, Walters BC, Grabb PA, Oyesiku NM, Przybylski GJ, Resnick DK, Ryken TC: Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 50 Suppl 2:S1, 2002
39. Hadley MN, Walters BC: Introduction to the guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 72 Suppl 2:5-16, 2013
40. Hansebout RR, Hansebout CR: Local cooling for traumatic spinal cord injury: Outcomes in 20 patients and review of the literature. J Neurosurg Spine 20(5):550-561, 2014
41. Hawryluk G, Fehlings M: Current status and future direction of management of spinal cord injury. In: Winn R, (ed), Youman’s Neurological Surgery. 6. Baskı, Philadelphia: Elsevier, 2006:2730-2740
42. Horvath K, Aschermann Z, Komoly S, Kovacs A, Kovacs N: Treatment of tardive syndromes. Psychiatr Hung 29:214-224, 2014
43. Huang H, Raisman G, Sanberg PR, Sharma H, Chen L: Neurorestoratology, cilt 2, New York: Nova Biomedical, 2015: 3-83
44. Huang H, Young W, Skaper S, Chen L, Moviglia G, Saberi H, Al-Zoubi Z, Sharma HS, Muresanu D, Sharma A, El Masry W, Feng S: Clinical Neurorestorative Therapeutic Guidelines for Spinal Cord Injury (IANR/CANR version 2019). J Orthop Translat 20:14-24, 2019
45. Juurlink BH, Paterson PG: Review of oxidative stress in brain and spinal cord injury: Suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med 21(4):309-334, 1998
46. Kamble SV, Motlekar SA, D’souza LL, Kudrigikar VN, Rao SE: Low doses of amitriptyline, pregabalin, and gabapentin are preferred for management of neuropathic pain in India: Is there a need for revisiting dosing recommendations? Korean J Pain 30:183-191, 2017
47. Karsy M, Hawryluk G: Pharmacologic management of acute spinal cord injury. Neurosurg Clin N Am 28(1):49-62, 2017
48. Kawabe J, Koda M, Hashimoto M: Granulocyte colonystimulating factor (G-CSF) exerts neuroprotective effects via promoting angiogenesis after spinal cord injury in rats. J Neurosurg Spine 15:414-421, 2011
49. Kitamura K, Fujiyoshi K, Yamane J: Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury. PLoS One 6:e27706, 2011
50. Koda M, Nishio Y, Kamada T: Granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into injured spinal cord and promotes functional recovery after compressioninduced spinal cord injury in mice. Brain Res 1149:223-231, 2007
51. Kopp MA, Liebscher T, Niedeggen A: Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury. Cell Tissue Res 349(1):119-132, 2012
52. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR: Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 4:451-464, 2004
53. Kwon BK, Mann C, Sohn HM: Hypothermia for spinal cord injury. Spine J 8:859-874, 2008
54. Kwon BK, Roy J, Lee JH: Magnesium chloride in a polyethylene glycol formulation as a neuroprotective therapy for acute spinal cord injury: Preclinical refinement and optimization. J Neurotrauma 26:1379-1393, 2009
55. Levi L, Wolf A, Belzberg H: Hemodynamic parameters in patients with acute cervical cord trauma: Description, intervention, and prediction of outcome. Neurosurgery 33(6):1007-1016, discussion 1016-1017, 1993
56. Liebscher T, Schnell L, Schnell D: Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 58:706-719, 2005
57. Lu P, Yang H, Jones LL: Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. J Neurosci 24(28):6402- 6409, 2004
58. Luo J, Borgens R, Shi R: Polyethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury. J Neurochem 83:471-480, 2002
59. Martirosyan NL, Patel AA, Carotenuto A, Kalani MY, Bohl MA, Preul MC: The role of therapeutic hypothermia in the management of acute spinal cord injury. Clin Neurol Neurosurg 154:79-88, 2017
60. McKerracher L, Anderson KD: Analysis of recruitment and outcomes in the phase I/IIa cethrin clinical trial for acute spinal cord injury. J Neurotrauma 30:1795-1804, 2013
61. Mofidi A, Bader A, Pavlica S: The use of erythropoietin and its derivatives to treat spinal cord injury. Mini Rev Med Chem 11:763-770, 2011
62. Nikolina E, Tidwell JL, Dai HN: The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. PNAS 101(23):8786- 8790, 2004
63. Ning GZ, Wu Q, Li YL: Epidemiology of traumatic spinal cord injury in Asia: A systematic review. J Spinal Cord Med 35(4):229-239, 2012
64. Ohbe H, Koakutsu T, Kushimoto S: Analysis of risk factors for hyponatremia in patients with acute spinal cord injury: A retrospective single-institution study in Japan. Spinal Cord 57(3):240-246, 2019
65. Park HC, Shim YS, Ha Y: Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng 11(5–6):913-922, 2005
66. Pelletier JH, Mann CH, German BT, Williams JG, Piehl M: Therapeutic systemic hypothermia for a pediatric patient with an isolated cervical spinal cord injury. J Spinal Cord Med 19:1- 4, 2018
67. Petitjean ME, Pointillart V, Dixmerias F, Wiart L, Sztark F, Lassié P: Medical treatment of spinal cord injury in the acute stage. Ann Fr Anesth Reanim 17(2):115-122, 1998
68. Plane JM, Shen Y, Pleasure DE: Prospects for minocycline neuroprotection. Arch Neurol 67(12):1442-1448, 2010
69. Rabchevsky AG, Fugaccia I, Turner AF: Basic fibroblast growth factor (bFGF) enhances functional recovery following severe spinal cord injury to the rat. Exp Neurol 164:280-291, 2000
70. Ryken TC, Hurlbert RJ, Hadley MN, Aarabi B, Dhall SS, Gelb DE: The acute cardiopulmonary management of patients with cervical spinal cord injuries. Neurosurgery 72 Suppl 2:84-92, 2013
71. Sahni V, Kessler JA: Stem cell therapies for spinal cord injury. Nat Rev Neurol 6(7):363-372, 2010
72. Schwartz G, Fehlings MG: Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: Improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 94 Suppl 2:245-256, 2001
73. Simard JM, Woo SK, Norenberg MD: Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma. Sci Transl Med 2(28):28-29, 2010
74. Song PW, Dong FL, Feng CC, Shen YN, Wang Y, Zhang RJ: A study of predictors for hyponatraemia in patients with cervical spinal cord injury. Spinal Cord 56(1):84-89, 2018
75. Streijger F, So K, Manouchehri N, Tigchelaar S, Lee JHT, Okon EB: Changes in pressure, hemodynamics, and metabolism within the spinal cord during the first 7 days after injury using a porcine model. J Neurotrauma 34(24):3336-3350, 2017
76. Tator CH, Koyanagi I: Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg 86(3):483-492, 1997
77. Teasell RW, Mehta S, Aubut JA, Foulon B, Wolfe DL, Hsieh JT: Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch Phys Med Rehabil 91:816-831, 2010
78. Turner N, Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10(2):116-129, 2010
79. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM: Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46:1551- 1556, 1996
80. Urbin MA, Ozdemir RA, Tazoe T, Perez MA: Spike-timingdependent plasticity in lower-limb motoneurons after human spinal cord injury. J Neurophysiol 118(4):2171-2180, 2017
81. Vale FL, Burns J, Jackson AB, Hadley MN: Combined medical and surgical treatment after acute spinal cord injury: Results of a prospective pilot study to assess the merits of aggressive medical resuscitation and blood pressure management. J Neurosurg 87(2):239-246, 1997
82. Wang SJ, Wang KY, Wang WC: Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125(1):191– 201, 2004
83. Wang X, Buddel S, Baughman K: Ibuprofen enhances recovery from spinal cord injury by limiting tissue loss and stimulating axonal growth. J Neurotrauma 26:81-95, 2009
84. Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW: Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126:1628-1637, 2003
85. White SR, Crane GK, Jackson DA: Thyrotropin-releasing hormone (TRH) effects on spinal cord neuronal excitability. Ann N YAcad Sci 553:337-350, 1989
86. Wollaars MM, Post MW, van Asbeck FW, Brand N: Spinal cord injury pain: The influence of psychologic factors and impact on quality of life. Clin J Pain 23:383-391, 2007
87. Wyndaele M, Wyndaele JJ: Incidence, prevalence and epidemiology of spinal cord injury: What learns a worldwide literature survey? Spinal Cord 44(9):523-529, 2006
88. Xu D, Yang L, Li Y, Sun Y: Clinical study of ganglioside (GM) combined with methylprednisolone (MP) for early acute spinal injury. Pak J Pharm Sci 28 Suppl 2:701-704, 2015
89. Yanagawa Y, Marcillo A, Garcia-Rojas R: Influence of posttraumatic hypoxia on behavioral recovery and histopathological outcome following moderate spinal cord injury in rats. J Neurotrauma 18(6):635-644, 2001
90. Yoon SH, Shim YS, Park YH: Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophagecolony stimulating factor: Phase I/II clinical trial. Stem Cells 25(8):2066-2073, 2007
91. Zhao RR, Andrews MR, Wang D: Combination treatment with anti-Nogo-A and chondroitinase ABC is more effective than single treatments at enhancing functional recovery after spinal cord injury. Eur J Neurosci 38:2946-2961, 2013
92. Zorner B, Schwab ME: Anti-Nogo on the go: From animal models to a clinical trial. Ann N Y Acad Sci 1198 Suppl 1:E22- 34, 2010

APA	boyali o, Civelek E, Kabatas S (2020). Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). , 466 - 474.
Chicago	boyali osman,Civelek Erdinç,Kabatas Serdar Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). (2020): 466 - 474.
MLA	boyali osman,Civelek Erdinç,Kabatas Serdar Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). , 2020, ss.466 - 474.
AMA	boyali o,Civelek E,Kabatas S Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). . 2020; 466 - 474.
Vancouver	boyali o,Civelek E,Kabatas S Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). . 2020; 466 - 474.
IEEE	boyali o,Civelek E,Kabatas S "Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)." , ss.466 - 474, 2020.
ISNAD	boyali, osman vd. "Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)". (2020), 466-474.

APA	boyali o, Civelek E, Kabatas S (2020). Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). Türk Nöroşirürji Dergsi, 30(3), 466 - 474.
Chicago	boyali osman,Civelek Erdinç,Kabatas Serdar Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). Türk Nöroşirürji Dergsi 30, no.3 (2020): 466 - 474.
MLA	boyali osman,Civelek Erdinç,Kabatas Serdar Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). Türk Nöroşirürji Dergsi, vol.30, no.3, 2020, ss.466 - 474.
AMA	boyali o,Civelek E,Kabatas S Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). Türk Nöroşirürji Dergsi. 2020; 30(3): 466 - 474.
Vancouver	boyali o,Civelek E,Kabatas S Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri). Türk Nöroşirürji Dergsi. 2020; 30(3): 466 - 474.
IEEE	boyali o,Civelek E,Kabatas S "Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)." Türk Nöroşirürji Dergsi, 30, ss.466 - 474, 2020.
ISNAD	boyali, osman vd. "Travmatik Omurilik Yaralanmasında Konservatif Tedavi (Güncel Farmakolojik Tedavi Yöntemleri)". Türk Nöroşirürji Dergsi 30/3 (2020), 466-474.